<DOC>
	<DOCNO>NCT02359214</DOCNO>
	<brief_summary>Supplementation study vitamin D perform cardiometabolic risk marker assess , result inconsistent . Hence , purpose study determine : 1 . Whether administer supplemental Vitamin D3 dose 5000IU/day ( 125µg ) overweight obese adult participant 8 week significantly increase circulate concentration 25 ( OH ) D achieve optimal vitamin D status . 2 . Whether administer supplemental Vitamin D3 dose 5000IU/day ( 125µg ) overweight obese participant 8 week significantly improve cardiometabolic parameter measure . 3 . To evaluate relationship variable 25 ( OH ) D concentration . We hypothesise significant increase plasma 25 ( OH ) D follow 8 week ( 56days ) supplementation oral vitamin D3 dose 5000IU/day ( 125µg ) ; Administering supplemental Vitamin D3 dose 5000IU/day ( 125µg ) overweight obese participant 8 week significantly improve cardio metabolic parameter measure , relationship variable 25 ( OH ) D concentration .</brief_summary>
	<brief_title>Effect Vitamin D3 Supplementation Cardiometabolic Risk</brief_title>
	<detailed_description>This study parallel randomise , double-blind placebo - control trial conduct University Chester , Chester , United Kingdom . Ethical permission obtain University Chester Faculty Research Ethics Committee ( 855/13/AT/CSN ) . Participants , especially students/staff recruit University Chester email , posters/leaflets . Males chosen study due high risk develop cardiometabolic disease compare premenopausal woman . The participant randomise receive either vitamin D supplement ( 5000IU ( 125µg ) /d ) placebo eight week . A computer generate random number sequence use assign participant intervention placebo group . Eligibility base 25 ( OH ) D assessment make screen visit baseline visit , participant plasma 25 ( OH ) D level ≤ 75nmol/l invited participate study . To ensure compliance intervention , participant send reminder intervention appointment email phone call . The study perform accord declaration Helsinki . All participant provide write consent . Study participant instruct store study supplement room temperature . All unconsumed supplement return counted ass compliance . MEASUREMENTS Dietary intake estimate baseline post intervention use three day food diary information health condition , medication health relate behavior assess pre-screen test questionnaire , physical activity evaluate average metabolic equivalent task ( MET-min/week ) use International Physical Activity Questionnaire . Participants assess baseline ( day 0 ) , day 28 56 . The plasma sample batch analyzed end trial . ANTHROPOMETRIC MEASUREMENTS Height ( m2 ) measure without shoe baseline , use stadiometer near 0.1cm precision , Body weight ( kg ) measure without shoe baseline post intervention use digital scale participant wear light indoor clothing , BMI calculate weight kilogram divide square height meter ( kg/m2 ) , waist circumference iliac crest measure tape measure subject standing . PULSE WAVE VELOCITY AND BLOOD PRESSURE MEASUREMENTS Participants give glass water allow rest 5 minute supine position afterwards pulse wave velocity meter ( Arteriograph ) cuff , measure arterial stiffness blood pressure place tightly round dominant arm . Overall , three measurement perform mean two measurement take . BIOCHEMICAL MEASUREMENTS A morning blood sample collect venepuncture antecubital vein accord standard protocol , participant sit position overnight fast least 8 hour . Blood sample draw 10ml lithium heparin EDTA tube avoid clot immediately transfer ice box centrifuge 10 minute four degree Celsius 3500rpm . Afterwards centrifuge plasma transfer aliquot store -80 degree Celsius analyze . CONDUCT OF THE STUDY This study require participant attend four clinic session four separate day . Clinic 1 ( day 0 ) : Participants expect complete consent form screen test questionnaire weight , height waist circumference measure . Afterwards , approximately 0.5ml blood collect finger prick put heparin tube avoid clot vitamin D status screen ascertain participant eligible partake study . Eligible participant invite take part study . Clinic 2 ( week 0 ) : Weight , height , waist circumference blood pressure body fat measurement perform . Afterwards , 25ml blood collect assess cardiometabolic risk marker . Participants randomise receive either vitamin D placebo ( without active ingredient ) supplement intervention period . Clinic 3 ( week 4 ) : The procedure perform clinic 2 repeat clinic . Clinic 4 ( Week 8 ) : The procedure perform clinic 2 repeat . It anticipate maximum length clinic visit 45mins . Participants expect complete three-day food diary physical activity questionnaire Clinic 2 4 . SAMPLE SIZE ESTIMATION The estimated sample size 58 ( 29 per group ) , sample size allow detection treatment difference 95 % power , 0.97 effect size 5 % significance . The power calculation base study ( Witham et al. , 2012 ) , primary outcome FMD ( flow mediate dilation ) parameter endothelial function estimate 29 per group obtain , allow loss follow , sample size increase 37 ( 25 % ) per group ( n= 74 ) . Sample size estimation conduct use G. Power version 3.1 software . DATA ANALYSIS Data check normal distribution use Shapiro-Wilk since n = 74 , homogenous variance assess Levene 's statistic . assumption normal distribution homogenous variance meet , parametric approach adopt , , non parametric approach adopt To assess difference group repeat measurement , perform Mixed Model Anova , difference observe analysed post- hoc , Tukey test . To check relationship variable 25 ( OH ) D , Pearson 's correlation conduct assumption meet spearman 's correlation assumption meet . Descriptive statistic consult determine finding differ baseline values.The mean standard deviation provide information change occur .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Bone Diseases</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Healthy male age 1865 year , Those BMI ≥ 25kg/m2 Those plasma 25 ( OH ) D concentration &lt; 75nmol/l Those gastrointestinal disease , cardiovascular disease , diabetes , osteoporosis , renal hepatic disorder Those take weight loss drug Those take cholesterol lower drug Those currently weight reduction programme Those blood pressure ≥ 160/90 mm Hg Those take vitamin D/calcium supplement</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Vitamin D</keyword>
	<keyword>Cardiovascular disease</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Obesity</keyword>
	<keyword>Cardiometabolic</keyword>
	<keyword>Bone disease</keyword>
</DOC>